한국발생생물학회지:발생과생식 (Development and Reproduction)

  • 제23권2호
  • /
  • Pages.119-128
  • /
  • 2019
  • /
  • 2465-9525(pISSN)
  • /
  • 2465-9541(eISSN)
한국발생생물학회 (The Korean Society of Developmental Biology)
권호 표지
DOI QR코드

DOI QR Code

Synergistic Enhancement of Paclitaxel-Induced Inhibition of Cell Growth by Metformin in Melanoma Cells

  • Ko, Gihyun (Dept. of Medicine, Jeju National University School of Medicine) ;
  • Kim, Taehyung (Dept. of Medicine, Jeju National University School of Medicine) ;
  • Ko, Eunjeong (Dept. of Medicine, Jeju National University School of Medicine) ;
  • Park, Deokbae (Histology, Jeju National University School of Medicine) ;
  • Lee, Youngki (Histology, Jeju National University School of Medicine)
  • 투고 : 2019.05.14
  • 심사 : 2019.06.08
  • 발행 : 2019.06.30
PDF 다운로드
⟨ 이전 논문 다음 논문 ⟩

초록

Melanoma is one of the most aggressive and treatment-resistant malignancies. Antidiabetic drug metformin has been reported to inhibit cell proliferation and metastasis in many cancers, including melanoma. Metformin suppresses the mammalian target of rapamycin (mTOR) and our previous study showed that it also inhibits the activity of extracellular signal-regulated kinase (ERK). Paclitaxel is currently prescribed for treatment of melanoma. However, paclitaxel induced the activation of ERK/mitogen-activated protein kinase (MAPK) pathway, a cell signaling pathway implicated in cell survival and proliferation. Therefore, we reasoned that combined treatment of paclitaxel with metformin could be more effective in the suppression of cell proliferation than treatment of paclitaxel alone. Here, we investigated the combinatory effect of paclitaxel and metformin on the cell survival in SK-MEL-28 melanoma cell line. Our study shows that the combination of paclitaxel and metformin has synergistic effect on cell survival and suppresses the expression of proteins involved in cancer metastasis. These findings suggest that the combination of paclitaxel and metformin can be a possible therapeutic option for treatment of melanoma.

키워드

참고문헌

  1. Aguirre-Ghiso JA, Ossowski L, Rosenbaum SK (2004) Green fluorescent protein tagging of extracellular signal-regulated kinase and p38 pathways reveals novel dynamics of pathway activation during primary and metastatic growth. Cancer Res 64:7336-7345. https://doi.org/10.1158/0008-5472.CAN-04-0113
  2. Cerezo M, Tichet M, Abbe P, Ohanna M, Lehraiki A, Rouaud F, Allegra M, Giacchero D, Bahadoran P, Bertolotto C, Tartare-Deckert S, Ballotti R, Rocchi S (2013) Metformin blocks melanoma invasion and metastasis development in AMPK/p53-dependent manner. Mol Cancer Ther 12:1605-1615. https://doi.org/10.1158/1535-7163.MCT-12-1226-T
  3. Chou TC, Talalay P (1981) Generalized equations for the analysis of inhibitions of Michaelis-Menten and higher-order kinetic systems with two or more mutually exclusive and nonexclusive inhibitors. Eur J Biochem 115:207-216. https://doi.org/10.1111/j.1432-1033.1981.tb06218.x
  4. Donadon V, Balbi M, Mas MD, Casarin P, Zanette G (2010) Metformin and reduced risk of hepatocellular carcinoma in diabetic patients with chronic liver disease. Liver Int 30:750-758. https://doi.org/10.1111/j.1478-3231.2010.02223.x
  5. Estrada Y, Dong J, Ossowski L (2008) Positive crosstalk between ERK and p38 in melanoma stimulates migration and in vivo proliferation. Pigment Cell Melanoma Res 22:66-76. https://doi.org/10.1111/j.1755-148X.2008.00520.x
  6. Ganesh T, Yang C, Norris A, Glass T, Bane S, Ravindra R, Banerjee A, Metaferia B, Thomas SL, Giannakakou P, Alcarez AA, Lakdawala AS, Snyder JP, Kingston DG (2007) Evaluation of the tubulin-bound paclitaxel conformation: Synthesis, biology, and SAR studies of C-4 to C-3' bridged paclitaxel analogues. J Med Chem 50:713-725. https://doi.org/10.1021/jm061071x
  7. Griss T, Vincent EE, Egnatchik R, Chen J, Ma EH, Faubert B, Violet B, DeBerardinis RJ, Jones RG (2015) Metformin antagonizes cancer cell proliferation by suppressing mitochondrial-dependent biosynthesis. PLOS Biol 13:e1002309. https://doi.org/10.1371/journal.pbio.1002309
  8. Gupta A, Love S, Schuh A, Shanyinde M, Larkin JM, Plummer R, Nathan PD, Danson S, Ottensmeier CH, Lorigan P, Collins L, Wise A, Asher R, Lisle R, Middleton MR (2014) DOC-MEK: A double-blind randomized phase II trial of docetaxel with or without selumetinib in wild-type BRAF advanced melanoma. Ann Oncol 25:968-974. https://doi.org/10.1093/annonc/mdu054
  9. He Y, Tan X, Hu H, Wang Q, Hu X, Cai X, Guan Y, Chen B, Jing X (2018) Metformin inhibits the migration and invasion of esophageal squamous cell carcinoma cells by downregulating the protein kinase B signaling pathway. Oncol Lett 15:2939-2945.
  10. Hersh EM, O'Day SJ, Ribas A, Samlowski WE, Gordon MS, Shechter DE, Clawson AA, Gonzalez R (2010) Phase II clinical trial of nab-paclitaxel in previously treated and chemotherapy-naive patients with metastatic melanoma. Cancer 116:155-163. https://doi.org/10.1002/cncr.24720
  11. Hodi FS, O'Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, Gonzalez R, Robert C, Schadendorf D, Hassel JC, Akerley W, van den Eertwegh AJ, Lutzky J, Lorigan P, Vaubel JM, Linette GP, Hogg D, Ottensmeier CH, Lebbe C, Peschel C, Quirt I, Clark JI, Wolchok JD, Weber JS, Tian J, Yellin MJ, Nichol GM, Hoos A, Urba WJ (2010) Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 363:711-723. https://doi.org/10.1056/NEJMoa1003466
  12. Joshua AM, Zannella VE, Downes MR, Bowes B, Hersey K, Koritzinsky M, Schwab M, Hoffman U, Ewans A, van der Kwast T, Trachtenberg J, Finelli A, Fleshner N, Sweet J, Pollak M (2014) A pilot 'window of opportunity' neoadjuvant study of metformin in localised prostate cancer. Prostate Cancer Prostatic Dis 17:252-258. https://doi.org/10.1038/pcan.2014.20
  13. Kim T, Kim T, Choi S, Ko H, Park D, Lee YK (2018) Combination of BEZ235 and metformin has synergistic effect on cell viability in colorectal cancer cells. Dev Reprod 22:133-142. https://doi.org/10.12717/DR.2018.22.2.133
  14. Kong F, Gao F, Liu H, Chen L, Zheng R, Yu J, Li X, Liu G, Jia Y (2015) Metformin use improves the survival of diabetic combined small-cell lung cancer patients. Tumor Biol 36:8101-8106. https://doi.org/10.1007/s13277-015-3549-1
  15. Kottschade LA, Suman VJ, Amatruda T 3rd, McWilliams RR, Mattar BI, Nikcevich DA, Behrens R, Fitch TR, Jaslowski AJ, Markovic SN (2011) A phase II trial of nab-paclitaxel (ABI-007) and carboplatin in patients with unresectable stage IV melanoma : A North Central Cancer Treatment Group Study, N057E(1). Cancer 117:1704-1710. https://doi.org/10.1002/cncr.25659
  16. Koul HK, Pal M, Koul S (2013) Role of p38 MAP kinase signal transduction in solid tumors. Genes Cancer 4:342-359. https://doi.org/10.1177/1947601913507951
  17. Lee J, Park D, Lee YK (2017) Metformin synergistically potentiates the antitumor effects of imatinib in colorectal cancer cells. Dev Reprod 21:139-150. https://doi.org/10.12717/DR.2017.21.2.139
  18. Li Q, Ma Z, Liu Y, Kan X, Wang C, Su B, Li Y, Zhang Y, Wang P, Luo Y, Na D, Wang L, Zhang G, Zhu X, Wang L (2016) Low doses of paclitaxel enhance liver metastasis of breast cancer cells in the mouse model. FEBS J 283:2836-2852. https://doi.org/10.1111/febs.13767
  19. McDaid HM, Horwitz SB (2001) Selective potentiation of paclitaxel (Taxol)-induced cell death by mitogenactivated protein kinase inhibition in human cancer cell lines. Mol Pharmacology 60:290-301. https://doi.org/10.1124/mol.60.2.290
  20. Nazarian R, Shi H, Wang Q, Kong X, Koya RC, Lee H, Chen Z, Lee MK, Attar N, Sazegar H, Chodon T, Nelson SF, McArthur G, Sosman JA, Ribas A, Lo RS. (2010) Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation. Nature 468:973-977. https://doi.org/10.1038/nature09626
  21. Niehr F, von Euw E, Attar N, Guo D, Matsunaga D, Sazegar H, Ng C, Glaspy JA, Recio JA, Lo RS, Mischel PS, Comin-Andix B, Ribas A (2011) Combination therapy with vemurafenib (PLX4032/RG7204) and metformin in melanoma cell lines with distinct driver mutations. J Transl Med 9:76-88. https://doi.org/10.1186/1479-5876-9-76
  22. Niraula S, Dowling RJ, Ennis M, Chang MC, Done SJ, Hood N, Escallon J, Leong WL, McCready DR, Reedijk M, Stambolic V, Goodwin PJ (2012) Metformin in early breast cancer: A prospective window of opportunity neoadjuvant study. Breast Cancer Res Treat 135:821-830. https://doi.org/10.1007/s10549-012-2223-1
  23. Ranchon F, Boespflug A, Rioufol C, Schwierta V, Thomas SL, Dalle S (2015) New treatments for cutaneous metastatic melanoma: MAPK pathway-targeted and immune based therapies. AntiCancer Agents Med Chem 15:461-467. https://doi.org/10.2174/1871520615666150101125028
  24. Schuler KM, Rambally BS, DiFurio MJ, Sampey BP, Gehrig PA, Makowski L, Bae-Jump VL (2015) Antiproliferative and metabolic effects of metformin in a preoperative window clinical trial for endometrial cancer. Cancer Med 4:161-173. https://doi.org/10.1002/cam4.353
  25. Shaw RJ, Lamia KA, Vasquez D, Koo SH, Bardeesy N, Depinho RA, Montiminy M, Cantley LC (2005) The kinase LKB1 mediates glucose homeostasis in liver and therapeutic effects of metformin. Science 310:1642-1646. https://doi.org/10.1126/science.1120781
  26. Tseng CH (2018) Metformin is associated with decreased skin cancer risk in Taiwanese patients with type 2 diabetes. J Am Acad Dermatol 78:694-700. https://doi.org/10.1016/j.jaad.2017.12.016
  27. Vancura A, Bu P, Bhagwat M, Zeng J, Vancurova I (2018) Metformin as an anticancer agent. Trends Pharmacol Sci 39:867-878. https://doi.org/10.1016/j.tips.2018.07.006
  28. Villanueva J, Vultur A, Lee JT, Somasundaram R, Fukunaga-Kalabis M, Cipolla AK, Wubbenhorst B, Xu X, Gimotty PA, Kee D, Santiago-Walker AE, Letrero R, D'Andrea K, Pushparajan A, Hayden JE, Brown KD, Laquerre S, McArthur GA, Sosman JA, Nathanson KL, Herlyn M (2010) Acquired resistance to BRAF inhibitors mediated by a RAF kinase switch in melanoma can be overcome by cotargeting MEK and IGF-1R/PI3K. Cancer Cell 18:683-695. https://doi.org/10.1016/j.ccr.2010.11.023
  29. Volk-Draper L, Hall K, Griggs C, Rajput S, Kohio P, De-Nardo D, Ran S (2014) Paclitaxel therapy promotes breast cancer metastasis in a TLR4-dependent manner. Cancer Res 74:5421-5434. https://doi.org/10.1158/0008-5472.CAN-14-0067
  30. Vujic I, Sanlorenzo M, Posch C, Esteve-Puig R, Yen AJ, Kwong A, Tsumra A, Murphy R, Rappersberger K Ortiz-Urda S (2014) Metformin and trametinib have synergistic effects on cell viability and tumor growth in NRAS mutant cancer. Oncotarget 6:969-978. https://doi.org/10.18632/oncotarget.2824
  31. Xu R, Sato N, Yanai K, Akiyoshi T, Nagai S, WadaJ, Koga K, Mibu R, Nakamura M, Katano M (2009) Enhancement of paclitaxel-induced apoptosis by inhibition of mitogen-activated protein kinase pathway in colon cancer cells. Anticancer Res 29:261-270.